Related Experiment Videos
[Low molecular weight heparins in everyday practice].
1Laboratoire central d'Hématologie, Hôtel Dieu de Paris.
Journal Des Maladies Vasculaires
|January 1, 1991
Summary
Standard heparin and low molecular weight heparin (LMWH) treat thromboembolic events. While LMWH offers improved pharmacokinetics, both heparin types present similar risks of bleeding complications.
Area of Science:
- Pharmacology
- Thrombosis Research
- Medical Chemistry
Context:
- Nonfractioned heparin (NFH) has been a standard treatment for thromboembolic disorders for decades.
- Hemorrhagic complications are a known risk associated with both NFH and low molecular weight heparins (LMWH).
- LMWH development was initially based on the hypothesis of a more favorable anti-Xa to anti-IIa activity ratio.
Purpose:
- To review the efficacy and safety of low molecular weight heparins (LMWH) compared to standard nonfractioned heparin (NFH).
- To discuss the pharmacokinetic advantages and clinical applications of LMWH.
- To evaluate the current understanding of LMWH's antithrombotic and hemorrhagic risk profile.
Summary:
- LMWH exhibits improved pharmacokinetic properties, such as longer duration of action and better bioavailability via subcutaneous administration, simplifying clinical use.
- Clinical trials indicate that LMWH's antithrombotic efficacy is comparable or superior to NFH.
- Despite theoretical advantages, LMWH does not appear to reduce hemorrhagic complication rates compared to NFH in postoperative phlebitis prevention.
Impact:
- LMWH has become a widely used alternative to NFH due to its favorable pharmacokinetic profile and comparable efficacy.
- Further research is needed to fully elucidate the risk-benefit profile of LMWH, particularly concerning hemorrhagic complications.
- The findings support the continued investigation into optimizing anticoagulant therapies for thromboembolic disease management.